Vision Marine Technologies' 180E Electric Powertrain Approved under California's CORE Voucher Program, Incentivizes Adoption of Electric Boat Propulsion
Key Highlights
Vision Marine's E-Motion™ 180E propulsion kits approved under California's CORE (Clean Off-Road Equipment) programUp to $170,000 per vessel in state-funded vouchers available for qualifying fleet operatorsApplies to both new electric boat builds and retrofit conversions using Vision Marine's certified installersCalifornia market includes approximately 4,400 commercially operated vessels across sectors such as ferries, harbor patrol, tour boats, rentals, and service craftApproval aligns with broader industry momentum toward electrification, strengthening Vision Marine's market position
MONTREAL, QC / ACCESS Newswire / June 18, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR), a developer of high-performance electric marine propulsion systems, announced today that its flagship E-Motion™ 180E powertrain has been approved for inclusion in California's CORE (Clean Off-Road Equipment) Voucher Incentive Project.
This approval makes Vision Marine's propulsion kits eligible for point-of-sale vouchers of up to $170,000 per unit, substantially reducing the cost of adopting electric propulsion for organizations modernizing their fleets.
"This represents a major milestone for Vision Marine, significantly enhancing our market position and accelerating our ability to drive widespread adoption of electric propulsion technology," said Alexandre Mongeon, CEO of Vision Marine Technologies.
California: A Strategic Market for Marine Electrification
California operates one of the largest and most dynamic commercially operated marine sectors in North America. With approximately 4,400 vessels in use across ferry services, water taxis, harbor patrol, tour operations, and rental businesses, the state presents a significant opportunity for electrification. Many of these segments are actively seeking clean alternatives to gas and diesel propulsion due to emissions regulations and increasing demand for quieter, lower-maintenance vessels.
Vision Marine's E-Motion™ 180E system-now listed under CORE-offers a compliant, high-performance solution for operators upgrading existing boats or commissioning new electric vessels.
Market Impact and Sales Potential
With this approval, Vision Marine can now offer its E-Motion™ 180E propulsion kits to eligible buyers with substantial financial support from the CORE program. Both new electric vessels and repower conversions are supported when completed by certified Vision Marine technicians and installers.
As the only 180 HP continuous electric powertrain listed under CORE, Vision Marine stands to benefit from increased demand across a wide range of commercial use cases. The company's commercial readiness, field-tested product, and established presence in California position it well to respond to immediate regional fleet electrification needs.
This milestone also comes as the global marine industry rapidly shifts toward clean propulsion. The combination of policy-driven funding and organic market demand creates a powerful tailwind for Vision Marine Technologies.
"California has long been a bellwether for clean technology adoption," added Mongeon. "Our CORE approval enhances our visibility and competitiveness in this key market, while reinforcing our ability to scale as electrification expands across North America."
About Vision Marine Technologies Inc.
Vision Marine Technologies Inc. (NASDAQ:VMAR) is a leader in high-performance electric marine propulsion. Its flagship E-Motion™ 180E system delivers 180 HP of continuous power through a fully integrated, scalable electric powertrain platform. Built for reliability and commercial-grade use, Vision Marine's solutions serve OEMs, fleet operators, government agencies, and rental services across North America.
For more information, visit: www.visionmarinetechnologies.com
About the CORE Program
The Clean Off-Road Equipment (CORE) Voucher Incentive Project is administered by the California Air Resources Board (CARB) and funded by the state's Cap-and-Trade program. CORE provides point-of-sale vouchers that help reduce the upfront cost of zero-emission off-road equipment, including marine technologies. The program is designed to accelerate the adoption of cleaner equipment and support California's climate and air quality goals.
To learn more, visit: www.californiacore.org
Forward-Looking Statements
Certain statements in this press release, including, but not limited to, statements regarding the anticipated benefits of the exclusive supply agreement, market expansion, and future events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Vision Marine disclaims any obligation to update these statements except as required by law. Actual results may differ materially from those expressed or implied. For a detailed discussion of these risks, refer to Vision Marine's Annual Report on Form 20-F for the year ended August 31, 2024, and other periodic filings with the SEC. Vision Marine does not undertake any obligation to update or revise forward-looking statements other than as required by law.
Investor Relations Contact:
Vision Marine Technologies Inc.Bruce Nurse - Investor Relationsbn@v-mti.com(303) 919-2193
Website: visionmarinetechnologies.com Twitter: @marine_visionFacebook: @VisionMarineTechnologiesInstagram: @visionmarine.technologiesYouTube: @VisionMarineTechnologies
SOURCE: Vision Marine Technologies Inc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Cizzle Brands Teams up Again With Coach Chippy to Launch Pink Lemon Flow, a New Flavour of CWENCH Hydration™
Building on the strong sales performance of "Tropical Flow", Cizzle Brands is launching a new limited-time variety of CWENCH Hydration™ in collaboration with Coach Chippy called "Pink Lemon Flow". Pink Lemon Flow will be sold exclusively in Sobeys Inc. banner stores in the grocery category, in addition to several sporting goods retailers, Life Time Fitness clubs, and select Petro-Canada gas stations. TORONTO, July 16, 2025--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (the "Company" or "Cizzle Brands"), is pleased to announce the launch of Pink Lemon Flow, a new limited-time flavour of CWENCH Hydration™ developed in partnership with long-time Cizzle Brands' collaborator, Coach Chippy. The launch of Pink Lemon Flow builds upon the success of Cizzle Brands' and Coach Chippy's Tropical Flow flavour of CWENCH which launched in January 2025, and has sold out its entire initial run including more than 20,000 cases of its ready-to-drink format. Starting in the second half of July 2025, Pink Lemon Flow will be carried in several different retail channels. In the grocery category, Pink Lemon Flow will exclusively be carried by banners of Sobeys Inc. in the grocery chain channel, including Sobeys and Safeway (in approximately 350 stores between the two chains), as well as all Longo's locations, and select locations of Thrifty Foods and Farm Boy (who began carrying CWENCH Hydration™ in March of 2025). The availability of Pink Lemon Flow at Sobeys is the first time the CWENCH Hydration™ brand is being launched at Sobeys. In addition to the Sobeys banners, many Canadian sporting goods retailers will be carrying Pink Lemon Flow, including Source for Sports, Sports Excellence, Pro Hockey Life, FGL Quebec, and Pure Hockey. Pink Lemon Flow will also be listed by select Petro-Canada locations, a gas station chain who has over 1,600 retail locations across the country. Additionally, Life Time Fitness will be offering Pink Lemon Flow at its fitness clubs in Canada and the United States. Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "Coach Chippy has grown to become one of the most influential icons in youth sports and it's awesome to be working with him again to launch Pink Lemon Flow. There's no one more enthusiastic about CWENCH Hydration™ than Chippy. We picked the Pink Lemon Flow flavour with Chippy because it offers a bright vibrant taste that people are going to love, especially during the summer season when hydration should be top of mind for everyone." Celenza added "Launching Pink Lemon Flow exclusively at Sobeys' banners in the grocery channel is also a big milestone for Cizzle Brands. We'll be sharing more details about the availability of our products at Sobeys in the coming weeks but suffice it to say we have a very exciting summer ahead of us as we team up with Coach Chippy and Sobeys to make Pink Lemon Flow, and CWENCH, remarkable successes." Regarding the launch of Pink Lemon Flow, Coach Chippy commented, "Summer was made for my Don't Think, Just Flow mentality. From driveway dangles, boardwalk blading, and staying fresh with the team — I wanted a drink that owned those moments. After seeing how fast Tropical Flow flew off the shelves, the team at CWENCH and I got to work. The result? Pink Lemon Flow — a crisp, tart pink lemonade with zero sugar and six electrolytes to keep you cool, dialed-in, and flow ready. It's a sip of summer in a bottle. Crack one. Stay hydrated. Let the flow take over." About Cizzle Brands Corporation Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 3,000 locations in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle. For more information about Cizzle Brands, please visit: For more information about CWENCH Hydration™, please visit: On behalf of the Board of Directors of the Company, CIZZLE BRANDS CORPORATION "John Celenza" John Celenza, Founder, Chairman, and Chief Executive Officer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change. View source version on Contacts For further information, please contact: Setti CoscarellaHead of Corporate Developmentinvestors@ 1-844-588-2088 Sign in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics ('the Company' or 'Amphista'), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck. In conjunction with the milestone achievement, Amphista receives a pre-specified financial payment. The associated target on which the milestone is triggered is currently undisclosed. 'As we continue to build our portfolio of first- and/or best-in-class Targeted Glues™, we are delighted to have reached an important milestone in our collaboration with Merck. The progress we have made together speaks to the effective partnership between scientists from both companies, enabling us to focus on advancing high-quality compounds for further development,' said Antony Mattessich, Chief Executive Officer at Amphista. 'This achievement reinforces the exceptional capabilities of our Eclipsys® platform in the rational design of orally bioavailable protein degraders, bringing us a step closer to improving patient outcomes.' Under the agreement, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys® platform. Merck is granted a global exclusive license to the resulting degrader molecules and will be responsible for further development and commercialisation activities. About Amphista Therapeutics At Amphista Therapeutics, we are focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disorders, through the discovery of advanced, next generation targeted protein degradation (TPD) medicines. Amphista applies its proprietary Eclipsys® platform to generate unique, sequentially bifunctional Targeted Glue™ therapeutics with a differentiated mechanism and leading drug-like properties. Our portfolio offers the potential to deliver first- and/or best-in-class therapeutics with performance characteristics beyond the limitations of CRBN and VHL-based agents. Amphista was co-founded by Advent Life Sciences and is additionally funded by a premier group of investors including Forbion, Gilde Healthcare, Novartis Venture Fund, SV's Dementia Discovery Fund and Eli Lilly. For more information, please visit: Amphista, Eclipsys, Targeted Glue, Targeted Glues and the Amphista logo are all trademarks or registered trademarks of Amphista Therapeutics Limited. For more information please contact: Amphista TherapeuticsJohn Goodall [email protected]
Yahoo
an hour ago
- Yahoo
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026. This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum. 'We appreciate CMS' proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,' said Kevin Hykes, President and CEO of CVRx. 'These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.' About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Forward Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about the proposal to maintain the APC for the Barostim implant procedure and progress toward expanded access to Barostim are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including the final OPPS rule, which could differ from the proposed rule, following the public comment period, and the actual impact of the APC on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@ Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@ in to access your portfolio
